Online inquiry

IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15158MR)

This product GTTS-WQ15158MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD6 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001254750.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 923
UniProt ID P30203
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15158MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4555MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ12992MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ11971MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ6607MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ190MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ7393MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ12938MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ5892MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW